Imunon releases new IMNN-001 data for AACR D3 presentation
Imunon released a July 23, 2026 announcement on a new IMNN-001 data set for presentation at AACR D3 in Boston, July 21-24.
The poster highlights Phase 2 OVATION-2 results: median overall survival of 40.5 months versus 27.6 months with chemotherapy alone; final results cited 45.1 versus 30.4.
The update also points to a rapidly recruiting Phase 3 OVATION-3 trial, positioned as pivotal for a potential BLA filing if successful.
IMNN•
